Case Name: WATSON PHARMACEUTICALS, INC. and Danbury Pharmacal, Inc., Plaintiffs-Appellants, v. Bernard A. SCHWETZ, D.V.M, Ph.D, Acting Principal Deputy Commissioner, U.S. Food and Drug Administration, Defendant-Appellee, and Bristol-Myers Squibb Company, Defendant-Appellee
Court: United States Court of Appeals for the Federal Circuit
Jurisdiction: United States
Decision Date: 2002-05-20
Citations: 38 F. App'x 578
Docket Number: No. 01-1285
Parties: WATSON PHARMACEUTICALS, INC. and Danbury Pharmacal, Inc., Plaintiffs-Appellants, v. Bernard A. SCHWETZ, D.V.M, Ph.D, Acting Principal Deputy Commissioner, U.S. Food and Drug Administration, Defendant-Appellee, and Bristol-Myers Squibb Company, Defendant-Appellee.
Judges: 
Reporter: West's Federal Appendix
Volume: 38
Pages: 578–578

Head Matter:
WATSON PHARMACEUTICALS, INC. and Danbury Pharmacal, Inc., Plaintiffs-Appellants, v. Bernard A. SCHWETZ, D.V.M, Ph.D, Acting Principal Deputy Commissioner, U.S. Food and Drug Administration, Defendant-Appellee, and Bristol-Myers Squibb Company, Defendant-Appellee.
No. 01-1285.
United States Court of Appeals, Federal Circuit.
May 20, 2002.

Opinion:
ON MOTION
ORDER
Bristol-Myers Squibb Co., Watson Pharmaceuticals, Inc. and Danbury Phar-macal, Inc. move jointly to voluntarily dismiss with prejudice. The Acting Principal Deputy Commissioner consents.
Upon consideration thereof,
IT IS ORDERED THAT:
(1) The unopposed motion to dismiss is granted.
(2) The motion to transfer is moot.
(3) All sides shall bear their own costs.